# Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL

> **NCT06093841** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Shanghai Ming Ju Biotechnology Co., Ltd.** · enrollment: 46 (estimated)

## Conditions studied

- Lymphoma, Large B-Cell, Diffuse
- Follicular Lymphoma Grade 3B
- High-grade B-cell Lymphoma
- Mediastinal B-Cell Diffuse Large Cell Lymphoma

## Interventions

- **BIOLOGICAL:** Relmacabtagene Autoleucel
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT06093841
- **Lead sponsor:** Shanghai Ming Ju Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-11-03
- **Primary completion:** 2024-01-21
- **Final completion:** 2029-11-04
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2025-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06093841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06093841, "Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT06093841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*